GLP-1类似物治疗肥胖2型糖尿病患者疗效和安全性的meta分析

发布时间：2018-03-31 08:56

本文选题：meta分析　切入点：GLP-1　出处：《南京中医药大学》2015年硕士论文

【摘要】：目的：运用meta分析方法对GLP-1受体激动剂治疗肥胖T2DM患者的疗效和安全性做出评价。方法：以“艾塞那肽”、“百泌达”、“利拉鲁肽”、“诺和力”、‘"GLP-1"、"肥胖”、“糖尿病”为中文关键词,“Liraglutide"、"Exenatide"、" GLP-1"、"obesity"、"diabetes mellitus"为英文关键词,检索中国知网数据库(CNKI)、维普中文科技期刊数据库(VIP)、万方全文数据库、中国优秀硕士学位论文全文数据库(CMFD)、相关博士学位论文(CDFD)、 pubmed等数据库,检索时间起止为2005.01.01—2015.03.01。筛选出实验组用艾塞那肽或利拉鲁肽单药治疗,或联合其它降糖药物治疗,对照组予其它降糖药物(OAD或胰岛素)治疗的随机对照试验。对纳入研究的文献进行风险评估和质量评价,提取资料和数据,运用Cochrane协作网提供的RevMan5.3.5软件进行数据的录入、分析。结果：共纳入10篇RCT研究,纳入研究中总共完整参加实验的有727例,其中实验组344例,对照组例383例。Meta分析结果：HbA1C (MD=-0.54,95%CI:-0.65～0.43, Z=9.98, p0.00001); TC[95%CI:-0.52 (-0.85,-0.19),Z=3.06, p=0.002]; TG[95%CI:-0.38 (-0.49,-0.26), Z=6.42, p0.00001]; BMI[95%CI:-2.36(-3.5,-1.23), Z=4.07, p0.0001];低血糖发生率[95%CI：-0.07(-0.16,0.02),Z=1.59,p0.05],差异没有统计学意义；胃肠道不适[95%CI0.31(0.14,0.48),Z=3.62,p=0.0003]；上消化道症状[95%CI0.3(0.12,0.48),Z=3.31,p=0.0009]；漏斗图基本都是对称、倒置图形。结论：利拉鲁肽或艾塞那肽能更有效的控制血糖、减轻体重及改善患者血脂情况,在副作用方面主要是胃肠道不适,尤其是上消化道不良反应,差异有统计学意义。其导致患者低血糖发生的概率同其它降糖药物相比是一样的,没有增加患者低血糖发生的风险。
[Abstract]:Aim: to evaluate the efficacy and safety of GLP-1 receptor agonists in the treatment of obese T2DM patients by meta analysis.To search the databases of CNKI, Weipu, Wanfang, CMFDN, CDFDN, pubmed and so on. The retrieval time is from January 1 to March 01, 2005.A randomized controlled trial was selected in which the experimental group was treated with either Isenapeptide or Lilarudine, or combined with other hypoglycemic drugs, while the control group was treated with other hypoglycemic drugs (OAD or insulin).The risk assessment and quality evaluation of the literature included in the study are carried out, the data and data are extracted, and the data input and analysis are carried out by using the RevMan5.3.5 software provided by the Cochrane Cooperative Network.Results: a total of 10 RCT studies were included, and a total of 727 subjects were included in the study, including 344 in the experimental group.Conclusion: Lilaru peptide or Isenapeptide can effectively control blood sugar, reduce body weight and improve blood lipids in patients. The main side effects are gastrointestinal discomfort, especially the adverse reactions of upper digestive tract. The difference is statistically significant.The risk of hypoglycemia is the same as that of other hypoglycemic drugs and does not increase the risk of hypoglycemia.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R587.1;R589.2

【参考文献】